It is highly possible that Stat5 reactivation in BCR-ABL- independent mechanisms may confer to CML LSCs preservation in BM microenvironment with treatment of IM. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.